Jeffrey Cohen, MD; Sarah Anderson, PharmD, NBC-HWC; and Alicyn Magruder, PharmD, BCACP, MSCS, share their final thoughts on the future landscape of clinical MS care in the biosimiliars era. [WATCH TIME: 12 minutes]
The associate professor of neuroscience at Lund University in Sweden discussed findings from a study of a new blood test examining biomarkers which demonstrated a high accuracy in identifying Alzheimer disease pathology. [WATCH TIME: 5 minutes]
The postdoctoral research fellow at Brigham and Women’s Hospital and Harvard Medical School discussed some of the issues with ensuring timely care access to approved therapies for patients with Duchenne muscular dystrophy. [WATCH TIME: 3 minutes]
The pediatric neurologist at the University of California, Davis, provided perspective on some of the mechanistic links between sleep and neurodevelopmental disorders. [WATCH TIME: 3 minutes]
The executive director of the Norman Fixel Institute for Neurological Diseases gave his call-to-action on how to change the approval system for neurologic devices for rare diseases.
The clinical assistant professor in the division of Sleep Medicine, Department of Neurology, University of Michigan spoke about the associations of mental health with insomnia in transgender youth. [WATCH TIME: 5 minutes]
Expert neurologists share thoughts on how to improve patient/physician communication and how listening to the patient needs will aid in managing MG.
Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.
The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the early reactions behind reflex tears as a potential biomarker for Parkinson disease. [WATCH TIME: 2 minutes]
Margaret Park, MD, and Russell Rosenberg, PhD, DABSM, provide clinical pearls and the future treatment landscape for the management of narcolepsy.v
The president of the American Heart Association discussed the necessary steps to increase access to systems of care in order to improve health overall, including the integration of telemedicine.
A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
Rachel Alvarez and Gustavo Dziewczapolski, PhD, of Cure CMD spoke about the benefits of attending the biennial Scientific & Family Conference to learn more about congenital muscle diseases and interact with the patient community.
The director of the Headache Center at Allegheny Health Network talked about the evolution of migraine treatments and highlighted the importance of personalized medicine for patients living with this disabling condition. [WATCH TIME: 10 minutes]
Sleeping Around the Podcast is joined by Rachel Nesmith, a patient with narcolepsy, who shares her story of overcoming the burdens and impairments of living with narcolepsy and cataplexy.
Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
The medical director of the Inpatient Rehabilitation Unit at Ascension Genesys Hospital discussed the importance of early intervention, sustained care, and rehabilitation in managing poststroke patients. [WATCH TIME: 4 minutes]
Scott Newsome, DO, and Ellen Mowry, MD, discuss the ongoing TREAT-MS trial and its goals, the importance of the findings for clinical practice in multiple sclerosis, and the ongoing discussion around induction vs escalation in MS treatment. [WATCH TIME: 24 minutes]
The chief medical officer of Wave Life Sciences outlined the FOCUS-C9 study, which has incorporated feedback from patients with both ALS and FTD, as well as investigators in the research field.
The professor from the Universite de Sherbrooke discusses the use of ketogenic diets and supplements to increase cognition.
The manager of Clinical Development-Research at Linus Health discussed potential avenues of research for the DCTclock and expanding its capabilities as a potential detector of cognitive decline. [WATCH TIME: 3 minutes]
The director of the John P. Hussman Institute for Human Genomics at the University of Miami detailed a new international initiative that expands on the genetic backgrounds of people of Hispanic and African ancestry. [WATCH TIME: 4 minutes]
The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine discussed observing how sleep may impact cognitive decline in different populations.
The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]
The postdoctoral scholar at the University of Iowa commented on why the multiple sclerosis field should lean on registered dietitians to help alleviate symptoms of patients with multiple sclerosis. [WATCH TIME: 2 minutes]
Current research pushes to advance therapeutic possibilities and understand underlying neural mechanisms for gait impairments in individuals with the disease.
The Muscular Dystrophy Association's annual meeting will take place in-person and virtually in Nashville, Tennessee, on March 13-16, with more than 950 in-person attendees and 130 presenters.
Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, share their hopes for the future of multiple sclerosis treatment and discuss unmet needs and novel targets.